Prolactin elevation with ziprasidone.
Shari I
SI
Lusskin
Robert
R
Cancro
Linda
L
Chuang
Jessica
J
Jacobson
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D019052:Depression, Postpartum / Q000188:drug therapy* / Q000453:epidemiology; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D018967:Risperidone